Conference Proceedings

PROfound: Phase III study of olaparib versus enzalutamide or abiraterone for metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene alterations

SK Sandhu, M Hussain, J Mateo, K Fizazi, F Saad, N Shore, K Chi, O Sartor, N Agarwal, D Olmos, A Thiery-Vuillemin, P Twardowski, N Mehra, C Goessl, J Kang, J Burgents, W Wu, A Kohlmann, C Adelman, J de Bono

ANNALS OF ONCOLOGY | OXFORD UNIV PRESS | Published : 2019

Grants

Funding Acknowledgements

AstraZeneca and Merck Sharp & Dohme Corp, a subsidiary of Merck & Co, Inc, Kenilworth, NJ, USA.